This subproject is one of many research subprojects utilizing the resources provided by a Shared Instrumentation Grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the grant, which is not necessarily the institution for the investigator. DESCRIPTION (provided by applicant): This application is a request for a Xenogen MS 100 Imaging System for in vivo fluorescence and bioluminescence imaging in live animals. Recent technological developments at CSHL have created a powerful pathway for discovery, characterization and validation of genes that contribute to the development and progression of cancer. These advances include the development of high-throughput genome scanning technology (ROMA) for identifying gene amplifications and deletions in cancer, the development of RNAi technology for assessing gene function and conducting high-throughput genetic screens for potential cancer drug targets, and the development of innovative new mouse models for rapidly understanding cancer gene function in vivo and for testing the action of new drugs or drug combinations. An emerging need in our animal modeling efforts is access to cutting edge in vivo imaging technology, and several CSHL investigators have been collaborating with outside investigators to use imaging methods to produce important new biological insights. These include the genetics of drug sensitivity and resistance, the utility of RNAi technology for gene therapy, and the location and the nature of stem cells in mice. The availability of a Xenogen MS 100 Imaging System on site will allow CSHL investigators to strengthen and broaden these efforts. Applications include monitoring tumor development, metastasis, tumor response to therapy, cell fusion and the expression of reporter gene in vivo. This system also allows 2 to 3 color imaging in the same mouse. Notably, since CSHL investigators do not have access to similar technology on site, the purchase of the Xenogen system provides an ideal, cost-effective, and versatile solution to our in vivo imaging needs. We believe that increased imaging capabilities provided by the Xenogen MS 100 Imaging System will contribute to the ability of the CSHL scientists to uncover new insights in cancer biology.
